Biohaven

Biohaven fails OCD trial but pushes on to phase 3 regardless
Fierce Biotech
Wed, 06/24/20 - 10:54 am
Biohaven
OCD
clinical trials
troriluzole
Ex-biotech chief pleads guilty in college admissions scandal, faces a 10-month prison stretch in plea deal
Endpoints
Tue, 05/26/20 - 10:04 pm
Harmony Biosciences
scandal
Biohaven
Bob Repella
Covid-19 adds a new danger to drug launches
EP Vantage
Fri, 04/17/20 - 10:46 am
drug launches
pandemic
COVID-19
Esperion
Biohaven
Urogen
Biohaven embraces digital to keep migraine launch on track despite COVID-19
Fierce Pharma
Wed, 03/25/20 - 11:54 pm
Biohaven
migraines
drug launches
digital pharma
COVID-19
pandemic
Nurtec
Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?
Endpoints
Thu, 02/27/20 - 11:46 pm
Biohaven
FDA
migraines
Nurtec
Allergan
AbbVie
Ubrelvy
In final report, ICER appears to have a change of heart on new acute migraine therapies
Endpoints
Tue, 02/25/20 - 10:40 am
ICER
migraines
Biohaven
Allergan
ubrogepant
rimegepant
Eli Lilly
Lasmiditan
New Meds Set to Reshape US CNS and oncology Markets
Xconomy
Tue, 02/18/20 - 08:36 pm
CNS
oncology
cancer
Clarivate Analytics
Biohaven
rimegepant
Novartis
OMB-157
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Biohaven Stock Slides More Than 8% on Drug Trial Failure
Motley Fool
Mon, 02/10/20 - 11:23 pm
Biohaven
troriluzole
clinical trials
generalized anxiety disorder
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
Thu, 01/30/20 - 10:43 am
FDA
Esperion Therapeutics
Acacia Pharma
Blueprint Medicines
Agile Therapeutics
Lundbeck
Sun Pharma
Biohaven
Durect Corporation
Migraine, cholesterol upstarts top the list of FDA decisions to watch this quarter
Fierce Pharma
Fri, 01/3/20 - 11:03 pm
FDA
migraines
cholesterol
Epizyme
tazemetostat
Esperion
bempedoic acid
teprotumumab
Horizon Therapeutics
Biohaven
rimegepant
First-of-its-kind trial in ALS spurs hope for brutal disease
BioPharma Dive
Wed, 09/25/19 - 11:35 pm
ALS
clinical trials
Implicit Bioscience
Prilenia Therapeutics
Clene Nanomedicine
Ra Pharma
Biohaven
In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug
Endpoints
Sat, 07/20/19 - 08:22 pm
Biohaven
FDA
riluzole
Apotex
ALS
Migraine patient or doctor? Demand more, Biohaven advises in new awareness push
Fierce Pharma
Tue, 07/16/19 - 11:06 pm
Biohaven
patients
migraines
pharma marketing
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Fierce Pharma
Fri, 07/12/19 - 09:50 am
Biohaven
migraines
CGRP blockers
rimegepant
Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time
Endpoints
Mon, 03/18/19 - 12:13 pm
Biohaven
migraines
rimegepant
40 Sites Across The Country To Test New Alzheimer's Drug
Forbes
Wed, 02/20/19 - 06:01 pm
clinical trials
Alzheimer's disease
troriluzole
Biohaven
Biohaven's orally dissolving tablet meets in Phase III for acute migraine
BioCentury
Mon, 12/3/18 - 06:01 pm
Biohaven
migraines
clinical trials
BHV3000-303

Pages